In a report released yesterday, Alistair Campbell from RBC Capital maintained a Buy rating on Pharming Group (PHGUF – Research Report), with a price target of €1.90. The company’s shares closed last Friday at $1.23.
According to TipRanks, Campbell is ranked #1547 out of 8498 analysts.
Pharming Group has an analyst consensus of Moderate Buy, with a price target consensus of $2.05.
See Insiders’ Hot Stocks on TipRanks >>
PHGUF market cap is currently $822.8M and has a P/E ratio of -50.40.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.
Read More on PHGUF:
